Tag Archives: ABBV

Therapix Biosciences Gets A Buy Rating From Laidlaw Analyst

Therapix Biosciences (NASDAQ:TRPX) received an initiation of coverage from Laidlaw & Company analyst Francois Brisebois who gave the company a Buy rating and a $18.00 price target. Therapix’s lead drug is an FDA approved dronabinol, which is a biosynthetic form of THC. The company’s strategy is to repurpose, reposition and improve the FDA approved cannabinoid for various conditions.

The analyst listed five key reasons for owning Therapix. These include:

The first condition the drug will address is Tourette Syndrome (TS), which has a high unmet medical need. Only three drugs re approved at this time and each has its drawbacks. They see the target population at 35,000. Phase2a data should be available in the fourth quarter of this year. In two controlled trials, THC has shown significant tic reduction in TS patients, but a high dose of THC caused unwanted psychoactive effects. Therapix believes that by combining the THC with PEA ( a fatty acide amide) increas es the efficacy, but cuts back on the bad side effects. It’s an encouraging piece of data that could be applied to other conditions. Encouraging pre-clinical data on ultra-low doses of THC for dementia patients holds big promise in the future. Phase 2a data to start in the first quarter of 2018. The analyst believes Therapix could be an acquisition target. Perhaps by one of its competitors in the same field like GW Pharmaceuticals (NASDAQ:GWPH) or AbbVie (NYSE:ABBV). The company recently uplisted to Nasdaq and a new CFO and US-based CEO.

Analyst Francois Brisbois wrote, “With encouraging pre-clinical data, a very large and growing target market, and a short Phase 1PK trial starting in 3Q17; we see real potential for the ultra-low dose platform at TRPX in the years to come.”

Laidlaw & Co. underwrote the Initial Public Offering for Therapix and then of course turned around and gave it a buy rating, which makes me wonder what happened to the Chinese Wall? So, I w as a bit skeptical at first, but have come to agree with the rating. The IPO priced at $6 and has jumped as high as $10.95. Lately, it is trading at roughly $6.94. So, the stock price has settled down since the initial pop.

For any emerging biotech company, an investor is looking toward the future. Therapix doesn’t anticipate any drug launches until 2020 and their first data won’t emerge until later this year. That’s a long time to wait for a catalyst and hope that the data results are positive. However, the same argument was made about GW Pharmaceutical in the early days and that stock has paid off handsomely for investors.

The investor demand for a cannabis stock with low risk will drive momentum for this company The Horizons Medical Marijuana Life Sciences ETF (HMMJ) and the potential First Trust Portfolios Medical Marijuana UIT would both be prime candidates to grab shares. Not to mention the many investors that might have missed their opportunity to buy GW Pharmaceutical when it was cheaper and have been waiting for a new name to enter the field.

Therapix is following other emerging biotech companies that have targeted the cannabinoid space. Abbvie was first to market wit h its dronabinol drug Marinol for nausea caused by chemotherapy. Unfortunately, patients don’t like the side effects and tend to drop the product. Marinol is only a small part of AbbVie’s drug portfolio and isn’t a easy comparison to Therapix. GW Pharmaceuticals is developing its Epidiolex drug, which targets epileptic patients. While, the stock has recently pulled back, it is still up 3% for the past year and over 900% for the past 5 years. Insys Therapeutics (NASDAQ:INSY) is also focused on the epilepsy patient population, but has run into legal problems associated with its sales practices a few years ago. Zynerba Pharmaceuticals is the most similar with its CBD product, but its stock price has also run up almost 90% over the past year.

Therapix isn’t projected to have any revenues until 2021 and losses will build in a run up to their first launch to prepare for marketing. The company is projected to report $7.6 million in losses for 2017. The success of the IPO sho uld keep the company in good shape until revenues start to roll in, assuming it is careful with its cash burn rates.

The patient population for TS isn’t huge, but of course if it helps these patients and that gets positive media coverage, it will boost the stock. Think Charlotte’s Web and CNN. They are a very long way from helping dementia patients, but that is a potential market of 46 million people worldwide and it seems to touch just about everyone you know. I think at this price, Therapix could deliver nice gains over time.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

SeekingAlphaAbout this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500. Become a contributor »Tagged: Investing Ideas, Quick Picks & Lists, Healthcare, BiotechnologyProblem with this article? Please tell us. Disagree with this article? Submit your own.Follow Debra Borchardt and get email alerts

how to invest

Gold (SPDR Gold Shares GLD) added 1.95% since the start of this year. Gold miners (VanEck Vectors Gold Miners GDX) soared more than 7% – outperforming almost every single ETF this year.

In this article, I want to explain how this could happen and what I think is going to happen next.

As most of you know, I wrote a few bearish articles during the past few months. Below are two of them.

Article: Gold (Miners) – Perfect Bear Case

Article: Gold (Miners): Breakdown Imminent

At first, I was quite successful when I started to become bearish on gold. However, gold exploded after my latest article. I always expected that something like this could happen. That is why I mentioned that my goal was to buy gold later instead of benefiting from a gold sell off. I only had a very small GDX short to prevent that I would get hurt during a rally like the one we just witnessed.

Click to enlarge

how to invest: NQ Mobile Inc.(NQ)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Thursday, telecommunications services shares gained by 0.42 percent. Meanwhile, top gainers in the sector included 8×8, Inc. (NASDAQ: EGHT), up 4 percent, and NQ Mobile Inc (ADR) (NYSE: NQ), up 2 percent.

  • [By Lisa Levin]

    NQ Mobile Inc (ADR) (NYSE: NQ) shares dropped 16 percent to $3.88 after the company issued an update on the FL Mobile divestment. NQ Mobile is expected to report Q4 financial results on March 21, 2016.

  • [By Belinda Cao]

    Oberweis China Opportunities Fund (OBCHX), the best-performing U.S.-based fund investing in Chinese stocks, said Internet companies from NQ Mobile Inc. (NQ) to Qihoo 360 Technology Co. (QIHU) will extend a rally after jumping more than three-fold this year.

how to invest: Gogo Inc.(GOGO)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Monday started the new week on a positive note, as the stock market once again recovered from early declines to post advances. The Dow Jones Industrials extended its string of record closes to 12 consecutive days in the wake of favorable comments from Warren Buffett about the valuation of the market. Moves within the Trump administration to transfer spending to the Defense Department also bolstered the overall market mood. In addition, good news from certain companies helped to sustain positive sentiment overall, and Advanced Micro Devices (NASDAQ:AMD), Windstream Holdings (NASDAQ:WIN), and Gogo (NASDAQ:GOGO) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Steve Symington]

    Shares of Gogo Inc. (NASDAQ:GOGO) were up 18.3% as of 1:30 p.m. EST Monday after the in-flight connectivity specialist announced stronger-than-expected fourth-quarter 2016 results.

  • [By Peter Graham]

    The Q4 2016 earnings report for small capin-flight WiFi stockGogo Inc (NASDAQ: GOGO) is scheduled for before the market opens onMonday (February 27th). Last summer, American Airlines did a deal with rival ViaSat, Inc (NASDAQ: VSAT) to provide Internet access on about 100 new Boeing jets. To add to the turbulence, Moody’s Investors Service assigned a B3 Corporate Family Rating, a B3-PD Probability of Default Rating and a SGL-2 Speculative Grade Liquidity Rating to Gogo Inc plus assigned a B2 (LGD3) rating to the Company’s $500 senior secured note offering (after a planned sale of $525 millionin junk bonds fell through). The Ratings Action noted:

  • [By Lee Jackson]

    Gogo Inc. (NASDAQ: GOGO) had a director purchasing a total of 300,000 shares at $9.69 per share. The total for the purchase was posted at $3 million.Gogo provides communications services to the commercial and business aviation markets in the United States and internationally. Itsstock was trading on Friday at $8.85.

how to invest: 3M Company(MMM)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Second, how will the Dow get to that big magic number? Well, the six biggest stock weightings in the DJIA are: Goldman Sachs (GS), 3M (MMM), International Business Machines (IBM), UnitedHealth Group (UNH), and Boeing (BA). What you will notice looking at a day like yesterday is that tech led the way sector wise. If the Dow is going to outperform, we need mega caps to outperform. We need those six stocks to outperform. So we need a day where financials and industrials outperform to get there. Given the trends in sector leadership, that is bound to happen…We are one Trump tweet talking about how yuuuuuuge Goldman Sachs is away from 20k.

  • [By Ben Levisohn]

    Time To Favor Optionality: Most macro data are similar to, or better than, when the merger was announced. As a result, the same returns have been obtainable, with significantly less stress, simply through owning 3M (MMM) or a basket of chemical companies that approximate the Dow-DuPont portfolio. Relative to the chemical sector, performance has been average, leverage appears reasonable but near-term FCF less-than compelling partly due to new capacity ramping. With the merger likely to close in the near-term (90% chance, in our view), we believe Dow-DuPont will have an opportunity to show how scale creates optionality. The overhaul at Celanese (CE) over the past few years shows the way.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded up 0.75% at $191.74. The stock’s 52-week range is $163.05 to $192.14, and the high was posted this afternoon. Volume was about 40% above the daily average of around 1.8 million shares. The company announced a $2 billion acquisition of the personal-safety unit of Johnson Controls.

  • [By Demitrios Kalogeropoulos]

    Investors looking for brighter prospects should consider two other blue-chip giants, 3M (NYSE:MMM) and Johnson & Johnson (NYSE:JNJ). Both are exposed to the consumer goods industry, but also get significant chunks of sales and profits from faster-growing segments.

how to invest: Repligen Corporation(RGEN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggested going long on small cap bioprocessing stock Repligen Corporation (NASDAQ: RGEN):

    As for Repligen, this one’s a bit more speculative than usual; we’re betting the long-term shape of the chart takes hold, and benefits us in the short run.

how to invest: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    AbbVie (ABBV) reported third quarter 2016 net sales increased a healthy 8% to $6.4 billion with net income increasing 29% to $1.6 billion and EPS increasing 31% to $.97.

  • [By Todd Campbell]

    AbbVie, Inc.(NYSE:ABBV) is already awaiting a Food and Drug Administration decision on its next-generation successor to Viekira Pak, and that successor is easier to dose than Viekira Pak, can be given over as few as eight weeks, and delivers high cure rates across genotypes.Those advantages could help stabilize AbbVie’s hepatitis C market share, which has declined in the past year.

  • [By Matt Hogan]

    After applying this technique to the 52 Dividend Aristocrats, there were two companies that stood out: Hormel Foods Corp (NYSE: HRL) and AbbVie Inc (NYSE: ABBV).

  • [By Keith Speights, Brian Stoffel, and George Budwell]

    Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.

  • [By Kumar Abhishek]

    The lower number of patient starts and rising competition has been a major worry for Gilead Sciences Inc. Most of the patients with serious Hep-C conditions have already been cured.It is estimated that more than 1 million Hep-C patients have been cured worldwide. And the entry of competitively priced drugs will further dent the growth of this segment. Gilead’s HCV drugs are facing tough competition from Merck (NYSE:MRK), AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY). For example, initially, the price difference between Merck’s treatment plan and Gilead’s plan was a whopping $40,000. The rising competition is also impacting the HCV segment’s margins.

  • [By George Budwell]

    If you’ve been following this stock for any length of time, you’re probably painfully aware that Gilead’s hep C franchise sank like a stone last year. The short version of the story is that the biotech’s super-aggressive pricing strategy for Sovaldi and Harvoni sowed discontent among payers, leading to a pricing war once rival drugs like AbbVie’s (NYSE:ABBV) Viekira Pak hit the market.

Pfizer Near A Technical Breakout

Pfizer (NYSE:PFE) has been gaining a lot of momentum recently with its share price having risen almost 7% since the 24th of January. The stock has been riding the biotech wave since the complex bottomed back in November but also has traded strongly since it announced its fourth quarter results at the end of January. Although the company missed earnings expectation in Q4 due to established products missing sales estimates, I still maintain the market is underestimating future earnings growth of Pfizer which is just over 5% per annum over the long term. This cautiousness to a certain extent may be warranted. Pfizer has struggled to keep up with peers in recent times with respect to new product launches and pending patent losses of Viagra & Lyrica also haven’t convinced the market as of yet that meaningful earnings growth is ahead of us.

I believe the pipeline is stronger than consensus believes but it is not only this area that has attracted me to this stock. I co ntinue to like this sector as I feel its fundamentals are robust, especially when you consider the sustained M&A activity that is present in this area. Pfizer’s share price won’t go to the moon but I believe there is strong downside protection here mainly due to the company’s sheer size and diversification. I think what dividend investors need to take into account here is that there are companies nowadays (which don’t have dividend aristocrat status) that are much better contenders for long term growth. Pfizer I feel is still feeling the ill effects of cutting its dividend back in the great recession and it is only slowly building its reputation once more in the dividend landscape. Here are three more strong reasons we will remain long Pfizer.

Firstly the company’s sheer size and significant cash flows have to be a major advantage in this sector especially when you consider the valuations some companies are going for at present. The cost of developing a new drug in this space can easily top $750,000, which is why it is becoming increasingly difficult for large cap companies in this space to keep their pipelines ahead of the curve so to speak. The smaller and less diverse a company is, the more risk it takes on when it attempts to develop new drugs through costly clinical trials. This is why many companies with weak pipelines are choosing the acquisition route to keep their top line elevated but companies with strong fundamentals continue to go for excessive valuations in this space. Pfizer does not have this problem. It brought in $7.2 billion in net income last year and another 6% growth in its bottom line is predicted this year.

This means at any time, it can undergo a heavy cycle of investment which i s something its competitors simply cannot do. What is the takeaway fro this over the long term? Well few drugs cross the line when it comes to intensive clinical trials so the more a company does, the more chances of success the respective company has in producing a blockbuster over time. Remember, Pfizer only needs one or two blockbusters every few years to ensure it can keep investing in its future. Therefore the law of probabilities states that this company should continue to produce solid outperformers over time – which in my opinion gives it a competitive advantage in this sector.

Technically although not generating the same returns as iShares NASDAQ Biotechnology Index (NASDAQ:IBB) since early November last year, Pfizer continues to make higher highs and has now broken up above its November highs. If Pfizer continues to trade up around these levels, I believe it will be only a matter of time before its daily moving averages cross over which would be a very bulli sh sign considering how the share price has traded in the past when its 50 day moving average crossed over with its 200.

Ibrance and Xeljanz growth trajectories remain critical in the near term as the market will continue attempt to gauge what sales will be from these drugs over the next few years. Although Ibrance has pretty stiff competition in the breast cancer area from the likes of Novartis (NYSE:NVS) and Eli Lilly (NYSE:LLY), Pfizer is taking advantage of first movers advantage here and is doing all it can to cement its brand behind the drug. Moreover Ibrance is still in its infancy internationally so growth rates should remain pretty elevated here. Xeljanz reported successful results recently in the rheumatoid arthritis area where the drug is believed to be able to be used as a combination therapy but not a standalone treatment. This means that Humira is still the lead drug in this space and the major cash cow of AbbVie (NYSE:ABBV) and will probably continue to be so for the next few years. However Xeljanz also can be marketed heavily internationally and with continued studies in areas such as ulcerative colitis & psoriatic arthritis, its tangible use should be improved meaningfully in the near term. The drug did $927 million in sales last year which was a 77% spike in growth on a rolling year basis. Impressive to say the least but I feel we are only getting started here.

To sum up, Pfizer’s exciting patents and strong pipeline should be enough to keep the top and bottom lines driving ahead over the next 3 years. This stock still looks a tad undervalued in my opinion.

Disclosure: I am/we are long PFE.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500. Become a contributor »Tagged: Investing Ideas, Long Ideas, Healthcare, Drug Manufacturers – MajorProblem with this article? Please tell us. Disagree with this article? Submit your own.

good stocks to invest in now

A few things will need to happen for oil to reach and hold $60 a barrel, as it has started its march in that direction and recently jumped above $54. The new OPEC deal, largely supported by many other producing nations, will need to hold. U.S. shale production cannot pick up too quickly. The signs of a global economic rebound cannot be interrupted.

On top of all that, the IEA Oil Market Report forecasts a drop in petroleum reserves early next year. What this means is that $60 oil prices are not just possible, but likely. With $60 oil, comes $3 a gallon gasoline.

Gas was last at $3 in mid-2014, based on the price of a gallon of regular. It rallied again in late 2015, but fell short by a few cents. During much of that time, oil traded north of $50, and during some of the period $60 or better. As far as gas prices are concerned, seasonality played a part. Memorial Day and Labor Day had their traditional spikes.

Gas prices based on a nationwide average have hovered around $2.30 recently. As is always the case, the price in certain parts of California and Hawaii is already at or near $3. In states close to the Gulf of Mexico and the Houston refineries, the price is below $2. In Texas, the average price for gallon of regular is $1.92.

good stocks to invest in now: Snap Interactive, Inc. (STVI)

Advisors’ Opinion:

  • [By Vikram Nagarkar]

    According to recent reports, Snap Inc will now look to go public at a valuation of $19 billion to $22 billion, as it goes public under the ticker symbol SNAP on the New York Stock Exchange. Snap Inc’s move to slash its previous seemingly overambitious target of $25 billion comes across as a very good move. Well, there’s no denying the fact that the upcoming Snapchat IPO has generated a lot of investor interest – to the extent that some “overeager” investors even went ahead and bought shares of a similar sounding company,Snap Interactive (OTC:STVI), sending its shares 140% higher. And Snap Interactive’s relatively paltry $50 million market cap may have something to do with it. Be that as it may, Snapchat’s reported initial valuation target of $25 billion was way too ambitious, and there’s no lack of consensus on that front. However, even the scaled down $19 billion target may not be attractive enough.

good stocks to invest in now: Mitsubishi UFJ Financial Group Inc(MTU)

Advisors’ Opinion:

  • [By Jim Jubak, Senior Markets Editor, MoneyShow.com]

    The one currency that is running against the weak dollar tide is the Japanese yen. The yen initially climbed on the Fed’s no taper decision—rising to 97.75 on the news—but then fell all the way back to 99 yen to the dollar and finished yesterday at 99.42. (Remember that since the yen is quoted in yen to the dollar, a higher number is a sign of a weak yen and a smaller number means the yen is getting stronger.) The thinking seems to be that the recent Japanese trade deficit will push the Bank of Japan to further weaken the yen, in order to boost Japanese exports. I continue to think that the yen will finish 2013 at weaker levels than current trading, and that leads me to continue to hold positions in Japanese stocks such as Toyota Motor (TM) and Mitsubishi UFJ Financial Group (MTU). Both stocks are members of my Jubaks Picks portfolio.

good stocks to invest in now: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    The lower number of patient starts and rising competition has been a major worry for Gilead Sciences Inc. Most of the patients with serious Hep-C conditions have already been cured.It is estimated that more than 1 million Hep-C patients have been cured worldwide. And the entry of competitively priced drugs will further dent the growth of this segment. Gilead’s HCV drugs are facing tough competition from Merck (NYSE:MRK), AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY). For example, initially, the price difference between Merck’s treatment plan and Gilead’s plan was a whopping $40,000. The rising competition is also impacting the HCV segment’s margins.

  • [By Todd Campbell]

    AbbVie, Inc.(NYSE:ABBV) is already awaiting a Food and Drug Administration decision on its next-generation successor to Viekira Pak, and that successor is easier to dose than Viekira Pak, can be given over as few as eight weeks, and delivers high cure rates across genotypes.Those advantages could help stabilize AbbVie’s hepatitis C market share, which has declined in the past year.

  • [By Keith Speights, Brian Stoffel, and George Budwell]

    Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.

  • [By WWW.KIPLINGER.COM]

    AbbVie Inc. (ABBV) stock is having a market-beating year with its gain of more than 7%, and the dividend only pads that lead. Slow-but-steady growth is a basic part of the equation.

  • [By J.B. Maverick]

     The pharmaceutical and health care sectors are generally less vulnerable to volatile and cyclical market moves, and may be one of the safer bets in 2016. Major drug manufacturer AbbVie, Inc. (NYSE: ABBV) has performed well for investors, and there are plenty of reasons to believe it will continue to do so. It is difficult to find a stock that shows a return on equity (ROE) of 59.3%, more than double the industry average of 23.3%. In addition, the stock’s dividend yield of 3.76% is well above the S&P 500 average, and the company has stated its firm commitment to return income to investors with a growing dividend payout. With successful drugs such as Humira and Imbruvica, and promising new ones in the company’s development pipeline, AbbVie has experienced revenue growth from $14 billion to $23 billion since 2009, and analysts project earnings per share (EPS) in the neighborhood of $5 for 2016, which represents an increase of 17%.

  • [By Ben Levisohn]

    Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:

good stocks to invest in now: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

good stocks to invest in now: Movado Group Inc.(MOV)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wednesday was yet another record-setting day for the stock market, as the Dow climbed triple digits and the S&P 500 and Nasdaq Composite followed the venerable average to unprecedented heights. Economic data showing rising inflation made it more likely that the Federal Reserve will look to boost interest rates at its next Federal Open Market Committee meeting next month, and the ripples throughout the bond market sent many investors to consider stocks instead. Yet despite the substantial rally, some stocks missed out on the move higher, and American International Group (NYSE:AIG), Teck Resources (NYSE:TECK), and Movado Group (NYSE:MOV) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Dan Caplinger]

    Monday began on a down note for the stock market, as the Dow Jones Industrials fell back down below the 20,000 level. Major market benchmarks finished with losses of 0.6% to 0.8%, and some market commentators attributed the declines to nervousness about the Trump administration’s actions to clamp down on immigration. Others noted that the latest reading of U.S. economic growth showed a 1.9% rise in gross domestic product for the fourth quarter, finishing the year with an overall GDP increase of just 1.6%, down a full percentage point from 2015’s growth. Despite the overall sullen mood in the market, some stocks gained ground, and GoPro (NASDAQ:GPRO), Movado Group (NYSE:MOV), and IPG Photonics (NASDAQ:IPGP) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

Top 5 Safest Stocks To Own Right Now

Related TWTR Does Pok茅mon GO Pose National Security Risk? Putting Pok茅mon GO's Massive Popularity Into Perspective Is Twitter The Future Of News Broadcast? (Seeking Alpha) Related Credit Suisse Bullish On Antero Resources, Raises Price Target Baird Sees Antero Midstream As An 'Undervalued Long-Term Growth' Play; Upgrades To Outperform E&P Mid-Year 2016 Financial Overview: Stats All, Folks! (Part I) (Seeking Alpha)

Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday's regular session.

Twitter Inc (NYSE: TWTR) Jan17 22.0 Calls: 20500 @ ASK $1.20: 22k traded vs 2041 OI: Earnings 7/26 After Close $17.63 Ref Antero Resources Corp (NYSE: AR) Aug16 25.0 Calls: 7500 @ ASK $2.30: 11k traded vs 560 OI: Earnings 8/3 $26.06 Ref Mobileye NV (NYSE: MBLY) Fri 7/22 52.0 Calls (Wkly) Sweep: 1000 @ ASK $0.50: 1003 traded vs 0 OI: Earnings 8/4 $48.50 Ref Cliffs Natural Resources Inc (NYSE: CLF) 7/29 8.0 Calls (Wkly) Sweep: 1000 @ ASK $0.15: 1000 traded vs 1 OI: Earnings 7/28 Before Open $6.83 Ref Integrated Device Technology Inc (NASDAQ: IDTI) Nov16 22.0 Calls Sweep: 1520 @ ASK $1.85: 1520 traded vs 67 OI: Earnings 8/1 $20.64 Ref Fortuna Silver Mines Inc (NYSE: FSM) Aug16 7.5 Calls: 2496 @ ASK $1.65: 2502 traded vs 162 OI: Earnings 8/5 $8.81 Ref Melco Crown Entertainment Ltd (ADR) (NASDAQ: MPEL) 7/29 13.0 Calls (Wkly): 4300 @ ASK $0.30: 7000 traded vs 10 OI: Earnings 8/4 $12.22 Ref

Posted-In: Huge Call PurchasesNews Options Markets

Top 5 Safest Stocks To Own Right Now: Crestwood Equity Partners LP(CEQP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Crestwood Equity Partners LP (NYSE: CEQP) shares shot up 45 percent to $18.54 following the announcement of a new joint venture with Consolidated Edison, Inc. (NYSE: ED). Subsidiaries of both companies entered into an agreement on Thursday to form a joint venture in which they will jointly own and develop Crestwood’s existing natural gas pipeline and storage business in norther Pennsylvania and southern New York.

Top 5 Safest Stocks To Own Right Now: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By George Budwell]

    If you’ve been following this stock for any length of time, you’re probably painfully aware that Gilead’s hep C franchise sank like a stone last year. The short version of the story is that the biotech’s super-aggressive pricing strategy for Sovaldi and Harvoni sowed discontent among payers, leading to a pricing war once rival drugs like AbbVie’s (NYSE:ABBV) Viekira Pak hit the market.

  • [By Keith Speights, Brian Stoffel, and George Budwell]

    Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.

  • [By Ben Levisohn]

    Gilead will announce its 2Q Earnings and hold its conference call on Monday, July 25…Gilead is driven by Hepatitis C virus and HIV sales. We see HCV sales ~$200M below consensus due to continued pricing pressure globally and lower market share in Europe. The pricing pressure comes from a more negative mix shift in the US from greater Veterans Administration volumes (discounts ~75%) and 8 week usage which is 33% less than a full course of drug, a full quarter of the 32% price cut in Japan vs. one month in 1Q16, and a negative mix shift in Europe to lower-priced countries in Southern Europe. Lower market share in Europe is a result of aggressive price competition from AbbVie (ABBV)…

  • [By Ben Levisohn]

    Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:

  • [By kiplinger]

     Volatility is unnerving, but investors able to keep their heads can use it to their advantage. There’s sure to be a lot of heated political rhetoric in 2016 about limiting drug costs, for example. That could be a cue to shop for bargains among top-notch pharmaceutical firms such as AbbVie Inc. (ABBV).

    The company’s key product is Humira, a drug used to treat rheumatoid arthritis and similar conditions. Big pharmaceutical companies with a global reach will benefit long-term from a coming surge in health care spending in emerging markets.

Top 5 Safest Stocks To Own Right Now: Impax Laboratories, Inc.(IPXL)

Advisors’ Opinion:

  • [By Keith Speights]

    Impax Laboratories (NASDAQ: IPXL  ) could be watching more closely than Sanofi. The two companies reached a deal last year that allows Impax to begin marketing a generic version of Renvela in 2014. If approved, Zerenex could take away some of the profits that Impax expected to gain.

Top 5 Safest Stocks To Own Right Now: Heico Corporation(HEI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Heico Corp (NYSE: HEI) is estimated to post its quarterly earnings at $0.54 per share.

    Exa Corp (NASDAQ: EXA) is projected to post a quarterly loss at $0.08 per share on revenue of $16.68 million.

  • [By Shauna O’Brien]

    Heico Corp (HEI) announced on Thursday that it has agreed to purchase Lucix Corp, a manufacturer of military satellite, airborne, and ground systems.

    The terms of the deal were not disclosed, but HEI revealed that the acquisition could be completed within 60 days. The deal is expected to impact HEI’s earnings within the first year.

    Heico shares were up 67 cents, or 1.04%, during Thursday morning trading. The stock is up 46% YTD.

Top 5 Safest Stocks To Own Right Now: Pan American Silver Corp.(PAAS)

Advisors’ Opinion:

  • [By JPMorgan]

    The weak silver sentiment has raised PAAS’ dividend yield to 2.8% which we feel is well supported by PAAS’ strong balance sheet and its healthy liquidity position of $566mn. The company is also advancing two growth projects, expected to add 5moz of silver and 128koz of gold pa to its production from 2018. Its costs are also improving, helped by devalued operating currencies and productivity improvements. 

  • [By Jim Cramer]

    Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Metals & Mining industry and the overall market, PAN AMERICAN SILVER CORP’s return on equity significantly trails that of both the industry average and the S&P 500.

     

  • [By Javier Hasse]

    Other stocks moving in Friday’s after-hours session included:

    A. O. Smith Corp (NYSE: AOS), down 2.5 percent Pan American Silver Corp. (USA) (NASDAQ: PAAS), down 2.1 percent Stamps.com Inc. (NASDAQ: STMP), up 1.87 percent

    Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

  • [By Jim Cramer]

    The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Metals & Mining industry. The net income has significantly decreased by 231.0% when compared to the same quarter one year ago, falling from -$20.25 million to -$67.05 million.

     

  • [By Jim Cramer]

    Despite any intermediate fluctuations, we have only bad news to report on this stock’s performance over the last year: it has tumbled by 29.22%, worse than the S&P 500’s performance. Consistent with the plunge in the stock price, the company’s earnings per share are down 193.33% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock’s sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.